Boston’s Dana Farber Cancer Institute inked a licensing deal with Transgenomic Inc. for its “Cold PCR” technology, which is used to detect genetic mutations.
The polymerase chain reaction technology developed by the institute is more sensitive to mutations that standard PCR techniques, according to a press release.
Transgenomic said the deal gives it the right to commercialize the process, with plans to use it to detect cancer-related mutations using blood and urine samples or tissue samples of mostly normal cells.
